NewAmsterdam Pharma Files 8-K
Ticker: NAMSW · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1936258
Sentiment: neutral
Topics: sec-filing, 8-k, financial-reporting
TL;DR
8-K filed by NewAmsterdam Pharma, check for updates.
AI Summary
On November 20, 2024, NewAmsterdam Pharma Co N.V. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulation FD disclosure. No specific financial figures or significant corporate actions were detailed in the provided text.
Why It Matters
This 8-K filing indicates that NewAmsterdam Pharma Co N.V. is providing updated information to the SEC, which could include material disclosures relevant to investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing notification and does not contain specific financial or operational risks.
Key Players & Entities
- NewAmsterdam Pharma Co N.V. (company) — Registrant
- November 20, 2024 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The 8-K filing is for a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, reporting on Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits.
What is the exact name of the registrant?
The exact name of the registrant is NewAmsterdam Pharma Company N.V.
On what date was this report filed or the earliest event reported?
The date of the report, and the date of the earliest event reported, is November 20, 2024.
Where is NewAmsterdam Pharma Co N.V. incorporated?
NewAmsterdam Pharma Co N.V. is incorporated in The Netherlands.
What is the principal executive office address for NewAmsterdam Pharma Co N.V.?
The principal executive office address is Gooimeer 2-35, Naarden, The Netherlands, 1411 DC.
Filing Stats: 1,802 words · 7 min read · ~6 pages · Grade level 12.7 · Accepted 2024-11-20 07:07:03
Filing Documents
- d868860d8k.htm (8-K) — 53KB
- d868860dex991.htm (EX-99.1) — 35KB
- d868860dex992.htm (EX-99.2) — 21KB
- g868860ex99_2p10g1.jpg (GRAPHIC) — 352KB
- g868860ex99_2p11g1.jpg (GRAPHIC) — 164KB
- g868860ex99_2p12g1.jpg (GRAPHIC) — 124KB
- g868860ex99_2p13g1.jpg (GRAPHIC) — 199KB
- g868860ex99_2p14g1.jpg (GRAPHIC) — 346KB
- g868860ex99_2p15g1.jpg (GRAPHIC) — 202KB
- g868860ex99_2p1g1.jpg (GRAPHIC) — 448KB
- g868860ex99_2p2g1.jpg (GRAPHIC) — 740KB
- g868860ex99_2p3g1.jpg (GRAPHIC) — 186KB
- g868860ex99_2p4g1.jpg (GRAPHIC) — 287KB
- g868860ex99_2p5g1.jpg (GRAPHIC) — 265KB
- g868860ex99_2p6g1.jpg (GRAPHIC) — 254KB
- g868860ex99_2p7g1.jpg (GRAPHIC) — 217KB
- g868860ex99_2p8g1.jpg (GRAPHIC) — 199KB
- g868860ex99_2p9g1.jpg (GRAPHIC) — 174KB
- 0001193125-24-262125.txt ( ) — 6016KB
- nams-20241120.xsd (EX-101.SCH) — 3KB
- nams-20241120_def.xml (EX-101.DEF) — 14KB
- nams-20241120_lab.xml (EX-101.LAB) — 23KB
- nams-20241120_pre.xml (EX-101.PRE) — 15KB
- d868860d8k_htm.xml (XML) — 6KB
Forward-Looking Statements
Forward-Looking Statements Certain statements included in this Current Report on Form 8-K that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook" and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the Company's business and strategic plans, the Company's commercial opportunity, the therapeutic and curative potential of the Company's product candidate, the Company's clinical trials and the timing for enrolling patients, the timing and forums for announcing data, the achievement and timing of regulatory approvals, and plans for commercialization. These statements are based on various assumptions, whether or not identified in this Current Report on Form 8-K, and on the current expectations of the Company's management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to the approval of the Company's product candidate and the timing of expected regulatory and
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. EXHIBIT NUMBER EXHIBIT DESCRIPTION 99.1 Press Release, dated November 20, 2024. 99.2 NewAmsterdam Pharma Company N.V., November 20, 2024 TANDEM Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NewAmsterdam Pharma Company N.V. By: /s/ Michael Davidson Michael Davidson Chief Executive Officer Dated: November 20, 2024